KOSDAQMachinery043220

TS Nexgen

₩1,710 0.00%2026-11-18 close
Market Cap
₩28.2B
Turnover
₩0
Volume
0 shares
Shares out.
16.5M
PER
—
PBR
1.5×
EPS
-₩1,381
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

TS Nexgen: Continued Losses and Listing Uncertainty

TS Nexgen's revenue has fallen for two straight years since 2023, operating losses have persisted for four consecutive years through 2025, and audit and listing-eligibility issues now overlap with the question of whether the business can normalize.

  1. 1

    Revenue peaked at KRW 26.5 billion in 2023, then fell to KRW 21.5 billion in 2024 and KRW 14.5 billion in 2025; third-quarter 2026 revenue was KRW 961 million, down 67.0% year on year.

  2. 2

    Operating losses ran for four consecutive years from 2022 to 2025, with a 2025 operating margin of -40.4%, the lowest in the disclosed period. The company posted a small operating profit of KRW 4.18 million in the second quarter of 2026.

  3. 3

    Net loss attributable to controlling shareholders totaled KRW 22.8 billion over the last four quarters, and the debt-to-equity ratio rose to 99.1% at end-2025 from 56.1% in 2022.

  4. 4

    The audit opinion for fiscal 2024 was a disclaimer, and subsequent reports covered a listing-eligibility review and delisting procedures, followed by reports of a trading halt tied to an injunction application; the current trading status needs confirmation from the latest filings.

  5. 5

    The company positions its ESS business and nuclear power equipment sales as growth drivers, but the confirmed improvement so far is a quarterly swing to a small operating profit.

02

Business structure

TS Nexgen was founded in 1995 and listed on KOSDAQ in 2001. It makes power plant dampers, busway power distribution equipment, and medical devices. The business is organized into an industrial equipment division, an energy division, and a medical device division.

The industrial equipment division produces power plant dampers and marine desulfurization equipment for domestic and overseas customers such as power plants and petrochemical plants.

According to company materials, its dampers are custom-designed to customer specifications, and the company has been recognized for competitiveness in marine SOx equipment. The energy division manufactures and sells busway systems used for power distribution.

The medical device division works through a subsidiary developing a low-intensity focused ultrasound stimulation system, with clinical trials described for brain disorders including Alzheimer's disease, depression, and Parkinson's disease.

The company has made and sold ESS products since 2017 and in December 2024 acquired a stake in a battery technology firm to strengthen its ESS capabilities.

However, reports said the stake in its medical device subsidiary was written down to zero book value at end-2025, leaving the financial contribution of that segment uncertain. The industrial equipment business is described as relatively insulated from economic cycles because public-sector orders make up a high share.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩2.9B-₩900M−31.5%
2025Q4₩3.5B-₩1.9B−53.6%
2026Q1₩3.8B-₩300M−6.8%
2026Q2₩2B₩4,179,2660.2%
2026Q3₩1B-₩700M−69.8%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩25.5B-₩2.6B-₩9.7B−10.3%−20.3%56.1%
2023₩26.5B-₩1.7B₩39,148,357−6.5%0.1%52.4%
2024₩21.5B-₩5.7B-₩19.1B−26.6%−28.9%94.2%
2025₩14.5B-₩5.9B-₩38.6B−40.4%−220.3%99.1%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-16

04

Earnings analysis

Annual revenue rose from KRW 25.5 billion in 2022 to KRW 26.5 billion in 2023, up 4.1% year on year, then fell to KRW 21.5 billion in 2024, down 19.0%, and to KRW 14.5 billion in 2025, down 32.4%. 2023 was the largest year in the 2022 to 2025 span, and revenue has declined for two consecutive years since 2024.

Operating loss narrowed from KRW 2.62 billion in 2022 to KRW 1.72 billion in 2023, then widened to KRW 5.73 billion in 2024 and KRW 5.87 billion in 2025.

The operating margin deteriorated from -10.3% in 2022 and -6.5% in 2023 to -26.6% in 2024 and -40.4% in 2025 as losses grew while revenue shrank, which suggests fixed-cost burden rose relative to sales.

Net profit attributable to controlling shareholders turned positive at KRW 39.15 million in 2023 but was a loss of KRW 19.1 billion in 2024 and KRW 38.6 billion in 2025, two straight loss years.

Net income including non-controlling interests was a loss of KRW 20 billion in 2024 and KRW 37.7 billion in 2025, so the two measures differ.

Quarterly revenue peaked at KRW 3.79 billion in the first quarter of 2026 after KRW 3.51 billion in the fourth quarter of 2025, then fell to KRW 2.02 billion in the second quarter and KRW 961 million in the third quarter of 2026.

The fourth quarter of 2025 carried the largest losses in the period, with an operating loss of KRW 1.88 billion and a loss attributable to controlling shareholders of KRW 21.1 billion.

Press reports said the stakes in its medical device subsidiary and in the battery technology firm were impaired at end-2025, and how much of the fourth-quarter loss reflects these items needs confirmation from the periodic filings. Total liabilities at end-2025 were KRW 18.6 billion, and operating cash flow was negative KRW 5.18 billion.

05

Industry analysis

The company's main end markets are power generation equipment and marine environmental equipment. Dampers are used in thermal and nuclear power plants, and the company has noted that public-sector orders make up a large share, which reduces exposure to private capex cycles.

The company has said it is actively pursuing the nuclear power market, including additional selection for a Korea Nuclear Industry Association support program. Marine desulfurization equipment demand is tied to shipping emission regulations, so it depends on the shipping cycle and the regulatory environment.

For the ESS market, the company cited SNE Research estimates of growth from USD 40 billion in 2024 to USD 80 billion by 2035; because this figure comes through company commentary, it should be read as a projection rather than a confirmed market size.

Listed companies in the same sector with power generation exposure include Doosan Enerbility and BHI. The company's custom-design model differs from mass-production equipment makers, and its revenue scale has shrunk to KRW 14.5 billion in 2025.

Whether orders in nuclear and ESS translate into revenue recovery will determine its position relative to the sector.

06

Outlook

In 2025 the company said it would create a battery division to strengthen its ESS business and pursue battery-related projects with domestic and overseas customers. The plan builds on the December 2024 stake in the battery technology firm and is described as aimed at higher revenue and profit.

In contrast, the medical device segment's prospects are hard to gauge after the subsidiary stake was written down. On March 19, 2026, a filing showed the largest shareholder changed from a former fund to Enplus, a KOSPI-listed company holding 3.71%.

In June 2026, a conversion of a KRW 3.5 billion convertible bond was disclosed, issuing 563,607 new shares.

Listing-related items included a March 2026 review decision and a trading halt adjustment in April, and in June reports covered a delisting decision tied to a qualified audit opinion with a clearing-trade schedule.

Later reports said trading would stay halted pending a court decision on an injunction application, and a September 14, 2026 market notice lists an entry on the dismissal of a rehabilitation application.

The next checkpoints are the 2026 annual report, the audit opinion attached to it, and decisions by the court and the exchange on listing status. Whether the operating margin in the next periodic report keeps narrowing its losses will show whether the 2026 trend holds.

Because third-quarter 2026 revenue fell to KRW 961 million, the fourth-quarter revenue recovery is also a point to watch.

07

Valuation

PER
—
PBR
1.5×
ROE
-74.4%
EPS
-₩1,381
BPS
₩1,159
Dividend per share
₩0

Because net loss attributable to controlling shareholders has continued across the last four quarters, a price-to-earnings multiple is not meaningfully calculated. The price-to-book ratio, by contrast, sits above 1 times, which means the shares trade at a premium to book value.

At end-2025, total equity was KRW 18.7 billion, of which KRW 17.5 billion belonged to controlling shareholders, so how that equity base holds up against accumulated losses frames any multiple-based reading.

The 90% capital reduction in August 2025 was aimed at covering accumulated deficits, but it reduced the nominal capital figure and did not by itself change operating profitability. The company does not pay dividends, so dividend-based comparisons do not apply.

Over several years, losses have persisted apart from a small profit swing in 2023, and the operating profit in the second quarter of 2026 is a quarterly signal of recovery rather than a multi-year trend.

Because trading status and the listing decision are not settled, it is also necessary to confirm whether any market price reflects tradable conditions.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-16

08

Bull factors

Diversification plans

Beyond industrial equipment, the company presents ESS and nuclear power equipment sales as growth drivers. Building on the December 2024 stake in the battery technology firm, it has said it will expand battery-related business.

If public-sector damper orders hold up, they could serve as a base for the portfolio, although the revenue contribution of the new businesses is not yet visible in the disclosed results.

Signs of quarterly improvement

Operating profit in the second quarter of 2026 was KRW 4.18 million, a swing to profit. The third-quarter 2026 operating loss was KRW 671 million, a narrower loss than a year earlier.

The first-quarter 2026 operating loss of KRW 256 million was also smaller than the KRW 1.88 billion loss in the fourth quarter of 2025, which suggests partial cost control effects at the quarterly level.

Capital reduction to cover deficits

In August 2025 the board approved a 90% reduction in common shares, cutting paid-in capital from roughly KRW 79.6 billion to roughly KRW 7.96 billion. The company said the step was meant to cover accumulated deficits and improve its financial structure.

The reduction creates room to absorb past deficits, although it does not change operating profitability by itself.

09

Bear factors

Continued revenue decline

Annual revenue fell from its 2023 peak of KRW 26.5 billion to KRW 21.5 billion in 2024 and KRW 14.5 billion in 2025. Third-quarter 2026 revenue was KRW 961 million, down 67.0% from a year earlier.

After peaking in the first quarter of 2026, revenue has declined for two consecutive quarters, which weakens the case for a revenue rebound.

Accumulated losses and balance sheet strain

Operating losses ran for four consecutive years through 2025, with a 2025 operating margin of -40.4%. Net loss attributable to controlling shareholders totaled KRW 22.8 billion over the last four quarters.

The debt-to-equity ratio rose from 56.1% in 2022 to 99.1% in 2025, and operating cash flow was negative KRW 5.18 billion in 2025.

Audit and governance issues

The fiscal 2024 audit opinion was a disclaimer, and reports described a listing-eligibility review and delisting procedures that followed.

Reports also described a 2024 change in control involving capital raises, convertible bond exchanges, and property sales, which a shareholder group has characterized as a planned asset transfer; this is the group's claim rather than an established finding. Audit and governance concerns affect the premises of any assessment before financial figures are considered.

10

Risk factors

Listing status and trading

Filings tied the company to delisting grounds linked to its audit opinion. A June 2026 delisting decision for a qualified opinion and a clearing-trade schedule were reported, and later reports said trading would remain halted pending a court decision on an injunction.

A September 14, 2026 market notice lists a dismissed rehabilitation application. The latest trading status needs confirmation from DART and exchange disclosures.

Funding and debt risk

Reports said a KRW 12.5 billion bond with warrants triggered an acceleration of obligations after an adverse audit opinion in early 2025, and KRW 9 billion in short-term borrowings was raised.

A lawsuit over a convertible bond claimed about KRW 6.05 billion, and a court recommended a settlement of about KRW 2.1 billion. A KRW 3.5 billion convertible bond conversion in June 2026 issued 563,607 new shares. Total liabilities were KRW 18.6 billion at end-2025.

Impairments and subsidiary value

Press reports said the stake in the medical device subsidiary was written down to zero book value at end-2025, and that the battery firm stake also took an impairment that sharply reduced its carrying value. How these declines feed into business value should be checked against impairment items in the periodic filings. If impairments continue while new ventures remain unproven, the burden on equity could increase.

11

What to watch next

  1. March 31, 2027 (statutory filing deadline)

    Submission of the 2026 annual report and its audit opinion. This is the first point at which full-year 2026 revenue, operating results, and fourth-quarter figures appear in a periodic filing.

  2. Early 2027 (date not set)

    Whether preliminary fourth-quarter and full-year 2026 results are disclosed. If they are, check whether the revenue decline and narrowing operating losses seen through the third quarter continue.

  3. Date not set (court and exchange decision timing)

    The outcome of the injunction application, any listing-eligibility decision, and whether the trading halt is lifted. These results determine whether shares can trade and whether the listing is maintained.

12

Overall view

TS Nexgen's revenue has fallen for two consecutive years since its 2023 peak, and operating losses have persisted for four consecutive years from 2022 through 2025.

The company swung to a small operating profit of KRW 4.18 million in the second quarter of 2026, but third-quarter revenue of KRW 961 million was down 67.0% year on year.

Net loss attributable to controlling shareholders totaled KRW 22.8 billion over the last four quarters, and the debt-to-equity ratio rose to 99.1% at end-2025. Bullish points include ESS and nuclear equipment initiatives and the effort to cover deficits through a capital reduction.

Bearish points include an adverse audit history, reports of delisting procedures and trading halts, impairments, and debt-related litigation. Earnings-based multiples cannot be calculated, while the price-to-book ratio sits above 1 times.

Until both the business normalization and the listing status are clearer, the financial figures and the trading status should be read separately. The next checkpoints are the 2026 annual report with its audit opinion and any court or exchange decisions on listing.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. jobkorea.co.kr
  2. comp.wisereport.co.kr
  3. kpinfo.kr
  4. news.nate.com
  5. m.news.nate.com
  6. app.rndcircle.io
  7. topdaily.kr
  8. s-econ.kr
  9. tsnexgen.com
  10. marketbz.com
  11. news.nate.com
  12. news.nate.com
  13. topstarnews.net
  14. m.news.nate.com
  15. topstarnews.net
  16. m.news.nate.com
  17. topstarnews.net
  18. datatooza.com

Report written 2026-11-16 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis